BTIG Research Reiterates “Buy” Rating for Innate Pharma (NASDAQ:IPHA)

Innate Pharma (NASDAQ:IPHA)‘s stock had its “buy” rating reissued by stock analysts at BTIG Research in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $8.00 target price on the stock. BTIG Research’s price target suggests a potential upside of 302.01% from the stock’s previous close.

A number of other brokerages have also recently commented on IPHA. Leerink Partnrs cut shares of Innate Pharma from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 18th. Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 target price (down from $10.00) on shares of Innate Pharma in a report on Thursday, September 18th. HC Wainwright set a $5.00 target price on shares of Innate Pharma and gave the company a “buy” rating in a report on Wednesday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Innate Pharma in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Innate Pharma currently has a consensus rating of “Hold” and a consensus target price of $5.00.

Innate Pharma Stock Performance

Shares of NASDAQ:IPHA opened at $1.99 on Wednesday. Innate Pharma has a twelve month low of $1.29 and a twelve month high of $3.51. The firm has a 50 day simple moving average of $2.04 and a 200-day simple moving average of $2.04.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.